Biogen Idec has struck a second deal with Neurimmune, this time agreeing to purchase one of the company’s subsidiaries for up to US$427.5 M. With the acquisition Biogen Idec will gain access to three preclinical immunotherapy programmes for the treatment of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis. It will be responsible for the development and subsequent commercialisation of the drug candidates and Neurimmune will provide scientific support with its RTM™ (Reverse Translational Medicine) technology platform. The deal fits with Biogen Idec’s new strategic focus on neurology.